Novavax sends FDA application for its COVID-19 booster

Novavax Inc. NVAX, -0.07% stated Monday that it asked the Food as well as Drug Administration to accredit its COVID-19 booster for grownups. The firm’s key collection of protein-based shots obtained FDA permission in July. “We think our vaccination provides a wide, durable immune action versus a variety of variations,” Novavax CEO Stanley Erck claimed in a press release. Novavax stated offering a 3rd shot of its vaccination to grownups 6 months after obtaining the very first 2 Novavax shots increased antibody degrees that approached or surpassed degrees reported after the very first 2 shots. Novavax’s supply has actually decreased 71.0% this year, while the wider S&P 500 SPX, +0.37% is down 10.2%.